Medifast, Inc. (NYSE: MED) today announced that a recent study published in ‘The Journal of Eating and Weight Disorders’ shows that individuals taking appetite suppressant medications can expect double the weight loss when they combine their drug therapy with a medical protocol using Medifast Meal Replacement Supplements.
The 52-week study, conducted by researchers at the University of Missouri-Kansas City School of Medicine and Baylor College of Medicine shows that participants who consistently used Medifast Meal Replacements along with pharmacotherapy lost an average of 14% of their body weight in one year. This amount of weight loss is approximately double what is seen in university studies of obesity medications alone over the same time frame. In the study, more than 80% of the participants lost at least 5% of their body weight, which is more than double that found for other structured commercial weight loss programs.
Read The Full Article